华法令对心房颤动患者的抗凝效果与安全性研究

Safety and efficacy of warfarin to preventing thromboembolism in patients with atrial fibrillation

目的 评价华法令用于心房颤动患者抗凝治疗的效果与安全性。方法 选择符合研究标准的 2 2 3例心房颤动患者 ,随机分为华法令治疗组 112例与阿司匹林对照组 111例。治疗组给于华法令片 ,每次 2 .5mg ,第 1天每天 3次 ,第 2天每天 2次 ,然后每天 1次 ,治疗开始每两天复查 1次国际标准化比值 (INR)。稳定后每月复查 1次INR ,依据INR调整华法令用量 ,使INR保持在 2 .0～ 3.0之间。对照组给予阿司匹林 5 0mg ,每天 3次 .。每两周进行1次随访 ,随访期为 1年 ,观察血栓栓塞事件及有无出血情况。结果 华法令组的栓塞发生率为 1.8% ,阿司匹林组为4 .5 8% ,两组比较差异具有统计学意义 (P <0 .0 5 ) ,华法令组出血发生率为 3.6 % ,阿司匹林组为 1.83% ,两组比较差异无统计学意义 (P >0 .0 5 )。结论 心房颤动的患者使用华法令抗凝治疗 ,使INR保持在 2 .0～ 3.0之间 ,能有效的预防血栓栓塞事件的发生 ,不良反应轻微 ,临床用药安全。

Objective To evaluate the safety and efficacy of warfarin to preventing thromboembolism in patients with atrial fibrillation. Methods Two handreds twenty-three patients with atrial fibrillation according with entrance standard was randomly divided into warfarin group(n=112) and aspirin group(n=111). Warfarin group: does 2.5 mg triple in first day,twice in next day,once every day sequence. The does used in patients depend upon INR keeping between 2-3. Patients be followed every other week by special physician for discovering thromboembolism and bleeding events. Results Incidence of thromboembolism events in warfarin group is 1.8%. in aspirin group is 4.58%. There were market differencese between two groups(P< 0.05). Incidence of bleeding events in warfarin group is 3.6% vs 1.83%. There were no differencese between two groups(P> 0.05). Conclusion It is sefaty and efficacy to used warfarin INR keeping between 2-3 for preventing thromboembolism in patients with atrial fibrillation.